Now showing items 1-5 of 5
New insights into molecular mechanisms of sunitinib-associated side effects
(American Association for Cancer Research, 2011-12)
[Abstract] The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. ...
Fructose transporter Glut5 expression in clear renal cell carcinoma
[Abstract] Renal cell carcinomas (RCC) can be subclassified for general purposes into clear cell, papillary cell, chromophobe cell carcinomas and oncocytomas. Other tumours such as collecting duct, medullary, mucinous ...
Crossing paths in Human Renal Cell Carcinoma (hRCC)
[Abstract] Historically, cell-signaling pathways have been studied as the compilation of isolated elements into a unique cascade that transmits extracellular stimuli to the tumor cell nucleus. Today, growing evidence ...
Sunitinib-induced asthenia: from molecular basis to clinical relief
(Taylor & Francis, 2011-11-01)
[Abstract] Asthenia-fatigue syndrome (AFS) is defined as a persistent, subjective sense of tiredness related to cancer or its treatment and greatly impacts quality of life among cancer patients. All tyrosine kinase inhibitors, ...
Potential role of sugar transporters in cancer and their relationship with anticancer therapy
[Abstract] Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to introduce sugars through their plasma membrane. ...